DOCSLIB.ORG

Product Overview

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product Overview Pharmacin Sourcing Global sourcing service, from suppliers and products you can trust. Pharmacin was founded in 1986 and has been active in the field of pharma- If you require a product that is not listed in our enclosed raw material ceutical raw materials. In 2006, Pharmacin has become a 100% subsidiary overview, our expertise and Aurobindo’s worldwide network allow us to Aurobindo Pharma Ltd. Aurobindo is one of the top API manufacturing act like a virtual manufacturing company. We source globally for the raw compa nies in the world and also among the very few pharmaceutical materials to meet your specific requirements. companies that are vertically integrated with a presence in API and for- mulations segments and delivering innovative solutions. All of our activities are in line with current GMP/GDP directives. Pharmacin is fully compliant with the Falsified Medicines Directive and we only approve Pharmacin’s strength is the ability to seamlessly switch between the wide suppliers that have successfully completed the Pharmacin supplier qua- variety of customer requirements and actual production capability. With lification process. This way, we ensure safe and controlled trading. We a range of more than 1000 raw materials – from Active Pharmaceuti- have GMP classified cleanrooms for the conditioning of raw materials cal Ingredients (APIs) and excipients to herbs to extracts – Pharmacin into any size you require. provides solutions for the pharmaceutical, veterinary, food and cosmetic industry. Committed to a healthier life Pharmacin Sourcing Sourcing Pharmaceutical Raw Materials and Nutraceutical Ingredients. 2-Deoxy D-glucose Ammoniated Mercury USP Benzoyl peroxide hydrous DFG Calcium alpha ketoglutarate Abacavir sulfate* Ammonium adipate Benzydamine HCl Calcium ascorbate Acacia gum (Arabic gum) Ammonium benzoate Benzyl benzoate Calcium aspartate anhydrous Aceclofenac Ammonium carbonate Bergamot essential oil Calcium benzoate Acetazolamide Ammonium chloride Beta-Carotene 10% Calcium carbonate Acetone Ammonium citrate dibasic/tribas Betahistine* Calcium chloride dihydr. Acetyl N- methionine DL- Ammonium lactate soln Betaine anhydr. Calcium citrate Acetyl N- methionine L- Ammonium nitrate Betaine citrate Calcium citrate malate Acetylcysteine Ammonium propionate Betaine dihydrogen citrate Calcium citrate tetrahydrate Acetyl-L-carnitine HCl Amoxicillin Sodium Sterile* Betaine HCl Calcium copper edetate Acetylsalicylic acid Amoxicillin Trihydrate* Betaine monohydr. Calcium ferrous citrate Aciclovir Amphetamine sulfate Betamethasone Calcium fumarate Acriflavine DiHCl Amphotericin B Betamethasone dipropionate Calcium glubionate Acriflavine HCl Ampicillin + Sulbactam* Betamethasone sodium phosphate Calcium gluconate monohydr. Acriflavinium Chloride Ampicillin Sodium Sterile* Betamethasone valerate Calcium glycerophosphate Activesperes®VIT C PMg Ampicillin Trihydrate* Bethanechol chloride Calcium glycinate Adapalene Amylocaine HCl Bezafibrate Calcium hydrogen phosphatedihydr. Adenosine Anastrozole Bifonazole Calcium hydroxide Adenosine triphosphate disodium Apixaban Bimatoprost Calcium lactate pentahydr. salt (ATP) Apomorphine HCl Biotin (Vit.H) Calcium lactobionate Adeps solidus Aprepitant Biperiden HCl Calcium levulate dihydr. Adrenaline / Epinephrine Apricot flavour Bisacodyl Calcium levulinate Adrenaline HCl / Epinephrine HCl Arachis Oil Bismuth citrate Calcium lysinate Adrenaline tartrate / Epinephrine Arbutin Bismuth subcarbonate Calcium malate tartarte Argatroban Bismuth subgallas Calcium monoethylfumarate Agar (Agar-Agar) Arginine L- Bismuth subnitrate Calcium orotate dihydr. Alanine DL- Arginine L-aspartate Bismuth subsalicylate Calcium pantothenate Alanine L- Arginine-L- HCl Bisoprolol Fumarate* Calcium peroxide Alanyl-glutamine L- Aripiprazole* Boldine Calcium phosphate dibasic anhydr. Albendazole Armodafinil* Borage oil refined Calcium pidolate Alendronate sodium* Articaine HCl Borax / Sodium tetraborate Calcium polystyrene sulfonate Alfuzosin HCl Ascomycin decahydr. Calcium propionate Algae (Laminaria) Ascorbic acid (Vit.C) Boric acid Calcium pyruvate Alginic acid Ascorbyl palmitate Boron Citrate/gluconate Calcium saccharate Allantoin Asparaginic acid L- Bosentan Calcium sodium edetate Allopurinol Aspartame Boswellia serrata dry extract Calcium succinate Almond oil refined Atazanavir sulfate* Brandy flavour Calcium sulfate Almond oil virgin Atenolol Brimonidine Calcium undecylenate alpha lipoic acid Atomoxetine Hydrochloride* Brimonidine tartrate Camphor D- natural Alprazolam Atorvastatin* Brivudine Camphor racemic Alprostadil Atorvastatine calcium trihydr. Bromazepam Camphorated Opium Tincture Alumen dodecahydr. Atropine sulfate Bromelaine Camylofin Aluminium chloride hexahydr. Avocado oil Bromhexine HCl Candesartan Cilexetil* Aluminium Chlorohydrate Azathioprine Budesonide Cantharidin Aluminium magnesium silicate Azelaic acid Bufexamac Capecitabine Aluminium oxide colloidal heavy Azelastine Bumetanide Capsaicin Aluminium oxide hydrated light Azilsartan medoxemil* Bupivacaine HCl Capsaicin - synthetic Aluminium sulfate Azithromycine dihydr. Buprenorphine HCl Capsicum oil / Oleoresin capsicum Amantadine HCl Azorubine red (E122) Buspirone HCl Capsicum oleoresin Amantadine sulfate Bacitracin Butalbital Capsicum Tincture Ambrisentan Baclofen Butobarbital Captopril Ambroxol HCl Banana flavour Butylhydroxytoluene (BHT) Caramel flavour butterscotch Amiloride HCl Barbital Cabazitaxel Carbachol Aminobenzoic-4 acid (PABA) Barbital sodium Cadmium chloride Carbamazepine Aminocaproic acid Beclomethasone dipropionate Cadmium sulfate Carbidopa Aminolevulinic acid HCl (5-ALA) Beeswax white Caffeine (anhydr). Carbimazole Aminophenazone / Aminopyrine Benazepril Hydrochloride* Caffeine citrate Carbocysteine Aminopyridine-4 Benfotiamine Cajeput essential oil Carbomer 940 Amiodarone Bentonite Calamine Carbomer 974P Amisulpiride* Benzalkonium chloride sol. 50% Calcitriol Carbomer 980 Amitriptyline HCl Benzocaine Calcium acetate Carboxymethyl cellulose sodium Amlodipine Besylate* Benzoic acid Calcium acid pyrophosphate Carmellose sodium (CMC sodium) 2 Pharmacin Sourcing *) Aurbindo Pharma Ltd. Pharmacin Sourcing Carmine red (E120) Chondroitini sulfas Cortisone acetate Disodium phosphate Carnitine L- Chormium amino acid chelate Creatine monohydr. Disulfiram Carnosine L- Chromium 0.2% in Maltodextrin Crotamiton Dithranol / Anthralin Carvedilol premix Cyanocobalamin (Vit.B12) Dobutamine HCl Caspofungin acetate Chrysin Cyclizine HCl Dolutegravir* Cassiolamine 8% Ciclopirox olamine Cyclobenzaprine HCl Domperidone Maleate* Castor oil virgin Ciclosporine A Cyproheptadine HCl sesquihydr. Donepezil* Cedarwood essential oil Cilastatin sodium sterile* Cyproterone acetate Donepezil HCl Cefazoline (sterile) Cilostazol Cysteine L- Dopamine HCl Cefazoline sodium (sterile) Cimetidine Cystine L- Doripenem monohydrate sterile* Cefdinir* Cimetropium Bromide Dabigatran etexilate* Dorzolamide Cefixime Trihydrate* Cinacalcet Hydrochloride* Cineole / Dalfampridine* Doxazosin Mesylate* Cefprozil* Eucalyptol Danazol Doxepin HCl Ceftazidime (sterile) Cinnamon bark essential oil Dapsone Doxycycline hyclate Ceftibuten* Cinnarizine Daptomycin Doxylamine succinate Ceftriaxone (sterile) Ciprofibrate Darifenacin Hydrobromide* D-Ribose Ceftriaxone sodium (sterile) Citalopram Hbr* Darunavir propylene glycolate* Drofenine HCl Cefuroxime (sterile) Citric acid anhydr. Deanol bitartrate Dronabinol Cefuroxime Axetil* Citric acid monohydr. Deanol orotate Dronedarone Hcl* Cefuroxime Sodium (sterile) Citronella essential oil Decyl oleate Droperidol Celecoxib* Citrulline-L Deferasirox* Duloxetine* Cellulose acetate phtalate Citrus Aurantium / Citrus Deferoxamine mesylate Duloxetine hydrochloride Cellulose ed dispersibile RC581 Bioflavonoid 45% Dehydrocholic acid Dutasteride Cellulose PH 101 Clindamycin HCl Dehydroepiandrosteron(Prasteron) Echinacea dry extract 4% Cellulose PH 102 Clindamycin Palmitate Hcl* Deoxycholic acid Econazole nitrate Cephalexin Clindamycin phosphate Dequalinium chloride Efavirenz * Cephalosporin Clioquinol Dermatin Sulfate Egg plant dry extract Cetaline Clobazam Desonide Eletriptan Hydrobromide* Cetearyl alcohol & Ceteareth-20 Clobetasol-17-propionate Dexamethasone Emtricitabine* Cetiol® CC Clobetasone butyrate Dexamethasone sodium phosphate Emulsifying wax Cetearyl alc. poly Cetirizine L- Clomipramine HCl Dexamphetamine sulfate sorbate 60 Cetomacrogol 1000 / Eumulgin B-2 Clonazepam Dexketoprofen trometamol Enalapril maleate Cetrimide Clonidine HCl Dexpanthenol Enoxolone Cetrizine DiHCl Clopidogrel Bisulfate* Dexrazoxane Enrofloxacin Cetyl alcohol Cloprostenol sodium Dextromethorphan hydrobromide Entacapone* Cetyl ester wax Clotrimazole Dextrose/Glucose monohydr. Entecavir Cetyl palmitate Clove essential oil Diacerein Eosine sodium Cetylstearylalcohol Clozapine Diaminopyridine-(3,4) Ephedrine HCl Chamomile flower Coal tar Diazepam Eprosartan mesylate Charcoal activated Cobalt gluconate Diclofenac potassium Ergocalciferol (Vit D2) Cherry flavour Cocaine HCl Dicloxacillin Sodium* Ergotamine tartrate Cherry SD Cocamidopropyl betaine / Betaine Diethylstilbestrol / DES Ertapenem* Chloral hydrate CAP Diflucortolone valerate Erythromycin Chloramine T Cochineal Red 80 (E 124) Digoxin Erythromycin estolate Chloramphenicol Coconut oil refined Dihydrocodeine tartrate Escine Chlordiazepoxide Codeine Dihydroergotamine mesylate Escitalopram oxalate* Chlorhexidine diacetate Codeine HCl dihydr. Diltiazem HCl Esomeprazole Magnesium* Chlorhexidine DiHCl Codeine phosphate
Load more

Recommended publications
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Survey and Risk Assessment of Chemical Substances in Deodorants
    Survey and risk assessment of chemical substances in deodorants Suresh C. Rastogi & Gitte Hellerup Jensen National Environmental Research Institute Jeanne Duus Johansen National Allergy Research Centre Survey of Chemical Substances in Consumer Products, No. 86 2007 The Danish Environmental Protection Agency will, when opportunity offers, publish reports and contributions relating to environmental research and development projects financed via the Danish EPA. Please note that publication does not signify that the contents of the reports necessarily reflect the views of the Danish EPA. The reports are, however, published because the Danish EPA finds that the studies represent a valuable contribution to the debate on environmental policy in Denmark. Contents SAMMENFATNING 5 SUMMARY 7 1 INTRODUCTION 11 2 MARKET SURVEY AND PRODUCT SAMPLING 13 2.1 MARKET SURVEY 13 2.2 LEGISLATION 15 2.3 SAMPLING OF PRODUCTS AND CONTROL OF LABELLING 15 2.4 SELECTION OF PRODUCTS FOR ANALYSIS 18 3 ANALYSIS 19 3.1 MATERIALS 19 3.2 ANALYSIS 19 3.2.1 Sample preparation 19 3.2.2 Analysis of fragrance substances 19 3.2.3 Analysis of triclosan 20 4 RESULTS 21 5 RISK ASSESSMENT 27 5.1 DEODORANTS AND CONTACT ALLERGY 27 5.2 RISK ASSESSMENT – IN GENERAL 27 5.3 THE SELECTED FRAGRANCE SUBSTANCES 28 5.3.1 HYDOXYISOHEXYL 3-CYCLOHEXENE CARBOXALDEHYDE (HICC) 28 5.3.2 HYDROXYCITRONELLAL 32 5.3.3 ISOEUGENOL 33 5.3.4 CINNAMAL/CINNAMYL ALCOHOL 34 5.4 FARNESOL 35 5.5 COMMENTS CONCERNING OTHER FRAGRANCE SUBSTANCES 35 5.6 ALLERGEN LOAD OF FRAGRANCE SUBSTANCES 36 5.7 TRICLOSAN 36 6 DISCUSSION 38 7 REFERENCES 43 ANNEX 1 49 3 4 Sammenfatning Deodoranter anvendes dagligt af store dele af befolkningen og kan indeholde ingredienser, som visse duftstoffer og konserveringsmidler, der er hyppige år- sager til hudallergi.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann Et Al
    US 2014O127257A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann et al. (43) Pub. Date: May 8, 2014 (54) DERMATOLOGICALLY EFFECTIVE YEAST Publication Classification EXTRACT (51) Int. Cl. (75) Inventors: Yvonne Schiemann, Essen (DE); Mike A61E36/064 (2006.01) Farwick, Essen (DE); Thomas Haas, CI2P I/02 (2006.01) Muenster (DE); Mirja Wessel, Bochum A61E36/06 (2006.01) (DE) (52) U.S. Cl. CPC ............... A61K 36/064 (2013.01); A61K 36/06 (73) Assignee: EVONIK DEGUSSA GMBH, Essen (2013.01); CI2P I/02 (2013.01) (DE) USPC ...................................... 424/195.16; 435/171 (21) Appl. No.: 14/128,244 (22) PCT Fled: Jun. 14, 2012 (57) ABSTRACT (86) PCT NO.: PCT/EP2012/061263 The invention relates to a method for producing a dermato S371 (c)(1), logically active yeast extract, comprising the following steps: (2), (4) Date: Dec. 20, 2013 providing a preculture of the yeast cells, culturing the cells for (30) Foreign Application Priority Data at least fifteen minutes at a pH of 1.8-4, harvesting the cells and lysing the cells, and a yeast extract produced thereby and Jun. 29, 2011 (EP) .................................. 11171953.0 products comprising said yeast extract. Patent Application Publication May 8, 2014 Sheet 1 of 3 US 2014/O127257 A1 -0-Yarrowia------------ lipolytica -- Pichia CBS 1991 - A - Saccharomyces Cerevisiae Fig. 1 US 2014/O127257 A1 May 8, 2014 DERMATOLOGICALLY EFFECTIVE YEAST skin. Against the background of consumers’ uncertainty with EXTRACT respect to genetic engineering techniques, there is a particular demand for corresponding agents that can be regarded, 0001.
    [Show full text]
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome
    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
    [Show full text]
  • Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition
    J Neurogastroenterol Motil, Vol. 24 No. 2 April, 2018 pISSN: 2093-0879 eISSN: 2093-0887 https://doi.org/10.5056/jnm17145 JNM Journal of Neurogastroenterology and Motility Review Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition Kyung Ho Song,1,2 Hye-Kyung Jung,3* Hyun Jin Kim,4 Hoon Sup Koo,1 Yong Hwan Kwon,5 Hyun Duk Shin,6 Hyun Chul Lim,7 Jeong Eun Shin,6 Sung Eun Kim,8 Dae Hyeon Cho,9 Jeong Hwan Kim,10 Hyun Jung Kim11; and The Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility 1Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea; 2Konyang University Myunggok Medical Research Institute Daejeon, Korea; 3Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea; 4Department of Internal Medicine, Gyeongsang National University, College of Medicine, Jinju, Korea; 5Department of Internal Medicine, Kyungpook National University, School of Medicine, Daegu, Korea; 6Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea; 7Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea; 8Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea; 9Department of Internal Medicine, Sungkyunkwan University School of Medicine, Changwon, Korea; 10Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea; and 11Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea In 2011, the Korean Society of Neurogastroenterology and Motility (KSNM) published clinical practice guidelines on the management of irritable bowel syndrome (IBS) based on a systematic review of the literature. The KSNM planned to update the clinical practice guidelines to support primary physicians, reduce the socioeconomic burden of IBS, and reflect advances in the pathophysiology and management of IBS.
    [Show full text]
  • IBS Treatment
    TREATMENTS OF IBS Douglas A. Drossman, MD Co-Director UNC Center for Functional GI & Motility Disorders INTRODUCTION In recent years, there has been increased interest by physicians and the pharmaceutical industry regarding newer treatments for IBS. Before discussing these new treatments, it is important to consider the overall management strategy in IBS. This is necessary because patients with IBS exhibit a wide spectrum of symptoms of varying frequencies and degrees of severity. There is no one ideal treatment for IBS, and the newer medications may work best for only a subset of patients having this disorder. Therefore, the clinician must first apply certain general management approaches and, following this, treatment choices will depend on the nature (i.e., predominant diarrhea, constipation, or bloating, etc.) and severity (mild, moderate, severe) of the symptoms. The symptoms of IBS may have any of several underlying causes. These can include: (a) abnormal motility (uncoordinated or excessive contractions that can lead to diarrhea, constipation, bloating) (b) visceral hypersensitivity (lower pain threshold of the nerves that can produce abdominal discomfort or pain) resulting from the abnormal motility, stress or infection (c) dysfunction of the brain's ability to regulate these visceral (intestinal) activities. Treatments will vary depending on which of these possibilities are occurring. In general, milder symptoms relate primarily to abnormal motility, often in response to food, activity or stress, and/or visceral hypersensitivity. They are commonly treated symptomatically with pharmacological agents directed at the gut. However, more severe symptoms often relate to dysfunction of the brain-gut regulatory system with associated psychosocial effects, and psychological or behavioral treatments and antidepressants are frequently helpful.
    [Show full text]
  • Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones by Ming-Hsiu Yang Su
    Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones By Ming-Hsiu Yang Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy Chairperson Ryan A. Altman Michael D. Clift Apurba Dutta Michael F. Rafferty Jon A. Tunge Date Defended: April 26, 2017 The Dissertation Committee for Ming-Hsiu Yang certifies that this is the approved version of the following dissertation: Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones Chairperson Ryan A. Altman Date Approved: April 26, 2017 ii Abstract Ming-Hsiu Yang Department of Medicinal Chemistry, April 2017 The University of Kansas Fluorine plays an important role in drug design, because of some unique features imparted by fluorine. The incorporation of fluorine into small molecules can modulate molecular physicochemical properties, metabolic stability, lipophilicity, and binding affinity to the target proteins. However, few fluorinated molecules are biosynthesized by enzymes. This means incorporating fluorine into the molecules relies on synthetic methods. Thus, efficient synthetic strategies to access the molecules bearing a variety of privileged fluorinated moieties are important for drug discovery. Fluoroalkenes are an isopolar and isosteric mimic of an amide bond with distinct biophysical properties, including decreased H-bond donating and accepting abilities, increased lipophilicity, and metabolic stability. Moreover, fluoroalkenes can also serve as probes for conducting conformational analyses of amides. These potential applications require the development of efficient methods to access fluoroalkenes. In chapter 2, a Shapiro fluorination strategy to access peptidomimetic fluoroalkenes is demonstrated.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,044,466 B2 Cohen Et Al
    USOO9044466B2 (12) United States Patent (10) Patent No.: US 9,044,466 B2 Cohen et al. (45) Date of Patent: *Jun. 2, 2015 (54) ORAL COMPOSITIONS COMPRISINGA 2800/882 (2013.01); A61O II/00 (2013.01); ZINC COMPOUND AND AN A61K 45/06 (2013.01); A61 K47/02 (2013.01); ANT-MICROBAL AGENT (Continued) (58) Field of Classification Search (75) Inventors: Marvin Cohen, St. Louis, MO (US); CPC ...... A61K 8/27; A61 K33/30; A61K 31/4425 Susanne Cohen, St. Louis, MO (US); USPC ............................................................ 424/49 Robert G. Flynn, Dupo, IL (US) See application file for complete search history. (73) Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF (56) References Cited NEW YORK, Albany, NY (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 4,226,851 A 10/1980 Sompayrac patent is extended or adjusted under 35 4,692,262 A 9, 1987 Brown et al. U.S.C. 154(b) by 0 days. (Continued) This patent is Subject to a terminal dis claimer. FOREIGN PATENT DOCUMENTS CN 101780016 A T 2010 (21) Appl. No.: 13/204,595 WO WO-OOf 51559 A1 9, 2000 (22) Filed: Aug. 5, 2011 (Continued) OTHER PUBLICATIONS (65) Prior Publication Data International Preliminary Report on Patentability for International US 2012/003428O A1 Feb. 9, 2012 Application No. PCT/US2011/046831 dated Feb. 21, 2013. Related U.S. Application Data (Continued) (60) Provisional application No. 61/371,695, filed on Aug. Primary Examiner – Rachael E. Bredefeld 7, 2010, provisional application No. 61/371,696, filed (74) Attorney, Agent, or Firm — Harness, Dickey & Pierce, on Aug.
    [Show full text]
  • Breast Cysts and Aluminium-Based Antiperspirant Salts
    Breast cysts and aluminium-based antiperspirant salts Article Published Version Creative Commons: Attribution 4.0 (CC-BY) Open access Darbre, P. (2019) Breast cysts and aluminium-based antiperspirant salts. Clinical Dermatology: Research and Therapy, 2 (1). 128. Available at http://centaur.reading.ac.uk/88553/ It is advisable to refer to the publisher’s version if you intend to cite from the work. See Guidance on citing . Publisher: Scientific Literature All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement . www.reading.ac.uk/centaur CentAUR Central Archive at the University of Reading Reading’s research outputs online Clinical Dermatology: Research And Therapy Special Issue Article “Breast Cyst” Research Article Breast cysts and aluminium-based antiperspirant salts Philippa D Darbre* School of Biological Sciences, University of Reading, UK ARTICLE INFO ABSTRACT On the basis that aluminium-based antiperspirant salts are designed to block apocrine Received Date: July 17, 2019 Accepted Date: September 23, 2019 sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the Published Date: September 30, 2019 adjacent region of the body, it has been proposed that breast cysts may arise from KEYWORDS antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term usage. This review collates evidence that aluminium can be absorbed from dermal Aluminium application of antiperspirant salts and describes studies measuring levels of aluminium Breast cancer Breast cysts in breast tissues, including in breast cyst fluids.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]